Matches in Nanopublications for { ?s ?p "[In conclusion, all human ovarian cancers express immunologically-detectable levels of HER2, indicating that IHC measurement underestimates the true frequency of HER2-expressing ovarian cancers and may limit patient access to otherwise clinically meaningful HER2-targeted therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[In conclusion, all human ovarian cancers express immunologically-detectable levels of HER2, indicating that IHC measurement underestimates the true frequency of HER2-expressing ovarian cancers and may limit patient access to otherwise clinically meaningful HER2-targeted therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In conclusion, all human ovarian cancers express immunologically-detectable levels of HER2, indicating that IHC measurement underestimates the true frequency of HER2-expressing ovarian cancers and may limit patient access to otherwise clinically meaningful HER2-targeted therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1031928.RAhg-_p53mMJvlJldqwWuw0Mt0Bzd56CyLsI5MSRcIomw130_assertion description "[In conclusion, all human ovarian cancers express immunologically-detectable levels of HER2, indicating that IHC measurement underestimates the true frequency of HER2-expressing ovarian cancers and may limit patient access to otherwise clinically meaningful HER2-targeted therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1031928.RAhg-_p53mMJvlJldqwWuw0Mt0Bzd56CyLsI5MSRcIomw130_provenance.
- NP1031930.RAnDDF_sMry8opukdvsOadMa-OLhOuz_89hLr2ynLAAKs130_assertion description "[In conclusion, all human ovarian cancers express immunologically-detectable levels of HER2, indicating that IHC measurement underestimates the true frequency of HER2-expressing ovarian cancers and may limit patient access to otherwise clinically meaningful HER2-targeted therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1031930.RAnDDF_sMry8opukdvsOadMa-OLhOuz_89hLr2ynLAAKs130_provenance.